Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma reports developments tied to its next-generation chimeric antigen receptor, or CAR T-cell, therapy pipeline for patients with cancer. The company’s recurring updates center on ronde-cel, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate for large B-cell lymphoma, and LYL273, a GCC-targeted CAR T-cell product candidate for metastatic colorectal cancer and other GCC-expressing cancers.
Company news also covers clinical-trial activity, FDA designation updates, manufacturing capabilities at the LyFE Manufacturing Center, quarterly financial results, equity financing activity, licensing transactions, investor-conference participation and executive or governance changes.
Lyell Immunopharma (Nasdaq: LYEL) announced that senior management will join two May 2026 investor events focused on oncology.
They will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference/b) on May 19 and the on May 20, with live and replay webcasts on the investor website.
Lyell Immunopharma (Nasdaq: LYEL) reported Q1 2026 results and business updates on May 6, 2026. Key clinical milestones: PiNACLE pivotal trial additional data expected H2 2026, pivotal data mid-2027 with a BLA planned in 2027; PiNACLE-H2H Phase 3 dosing commenced; LYL273 dosing at Dose Level 3. Corporate: closed second $50M tranche at $25.61/share and held $261.0M cash as of March 31, 2026, which the company expects to fund operations into Q3 2027.
Lyell Immunopharma (Nasdaq: LYEL) said senior management will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 11:00 AM ET. A live webcast will be available via the company investor website, with a replay posted after the presentation.
The presentation covers Lyell's late-stage CAR T-cell therapy pipeline and provides an opportunity for investor questions and management commentary.
Lyell Immunopharma (NASDAQ: LYEL) reported Q4 and full-year 2025 results and business updates on March 12, 2026. Key developments include commencement of patient dosing in the Phase 3 PiNACLE-H2H trial (ronde-cel vs axi-cel/liso-cel) and ongoing PiNACLE pivotal and Phase 1 LYL273 programs.
Financials: net loss of $274.4M for 2025, cash of approx. $247.2M at year-end (excluding a subsequent $50M tranche), and a closed $50M equity tranche in March 2026 after a clinical milestone.
Lyell Immunopharma (Nasdaq: LYEL) closed an additional $50 million tranche of a July 2025 equity private placement after achieving a clinical milestone for rondecabtagene autoleucel in the PiNACLE pivotal trial for relapsed/refractory LBCL.
The tranche was sold at $25.61 per share, bringing total placement proceeds to ~$100 million; Lyell expects cash to fund operations into Q2 2027. Smital Shah was appointed Chief Financial and Business Officer effective March 9, 2026.
Lyell Immunopharma (Nasdaq: LYEL) said senior management will present at three investor conferences in early March 2026: TD Cowen (Mar 2, Boston), Leerink Annual Global Healthcare (Mar 9, Miami) and Citizens Life Science (Mar 10, Miami).
Live webcasts and on-demand replays will be available on the company website at www.lyell.com following each presentation.
Lyell Immunopharma (Nasdaq: LYEL) dosed the first patient in PiNACLE – H2H, a Phase 3 randomized head-to-head trial of rondecabtagene autoleucel (ronde-cel) versus liso-cel or axi-cel in second-line relapsed/refractory large B-cell lymphoma. The trial plans ~400 patients (200 per arm) and uses event-free survival as the primary endpoint.
Ronde-cel showed a 93% best overall response rate and 76% complete response rate in 29 efficacy-evaluable 3L+ patients; median progression-free survival was 18 months (data cutoff Sept 5, 2025). A BLA submission for the pivotal 3L+ trial is expected in 2027.
Lyell Immunopharma (NASDAQ: LYEL) presented new clinical and translational data for rondecabtagene autoleucel (ronde-cel) at ASH on Dec 7, 2025 showing high responses in large B-cell lymphoma (LBCL). In 3L+ patients (n=29 efficacy-evaluable) ronde-cel achieved a 93% ORR, 76% CR rate and median progression-free survival of 18 months. In 2L patients (n=18 efficacy-evaluable; 94% primary refractory) it showed an 83% ORR and 61% CR rate with durable CRs.
Safety was manageable for outpatient use: no Grade ≥3 CRS and ≤5% Grade ≥3 ICANS after dexamethasone prophylaxis. Two pivotal trials (PiNACLE – H2H and PiNACLE) are underway.
Lyell Immunopharma (NASDAQ: LYEL) on Nov 12, 2025 reported Q3 2025 results and program updates. Key clinical highlights include acquisition of global rights to LYL273 (GCC-targeted CAR T) with 67% ORR and 83% disease control at the highest dose in a U.S. Phase 1 mCRC trial, and FDA RMAT designation for ronde-cel in the 2L setting (complementing 3L+ RMAT).
Ronde-cel is advancing in PiNACLE (3L+ pivotal) and PiNACLE–H2H (Phase 3 2L randomized, ~400 patients, expected enrollment by early 2026). Cash and marketable securities were ~$320M at 9/30/2025, expected to fund operations into 2027. Q3 GAAP net loss was $38.8M.
Lyell Immunopharma (Nasdaq: LYEL) acquired exclusive global rights (outside mainland China, Hong Kong, Macau and Taiwan) to LYL273, a next‑generation GCC‑targeted CAR T candidate for metastatic colorectal cancer, on Nov 10, 2025. LYL273 showed a 67% overall response rate and an 83% disease control rate at the highest dose (2 x 10^6 CAR T cells/kg) in a U.S. Phase 1 trial (12 patients; data cutoff Oct 28, 2025) with median PFS of 7.8 months at that dose.
Transaction terms include a $40M upfront payment plus 1.9M Lyell shares, up to $820M additional cash milestones, equity milestones, and tiered royalties; Lyell says cash is expected to fund operations into 2027.